الفهرس 
Systemic Lupus ErythematosusOnly 14 pages are availabe for public view
 |  | from | 207 |  |  |
| | | from | 207 | | |
Abstract
Background: SLE is an important prevalent chronic autoimmune disease with female preponderance of 9:1. Treatment of the disease involves powerful immunosuppressive medications which have been implicated with ovarian failure and premature menopause. It has been speculated that disease activity is altered in different age spectrums and menstrual status.
Aim of the study: To identify menopause characteristics in an Egyptian cohort of women with SLE with effect of the disease on menopausal symptoms and the characteristics of disease activity and disease damage in peri- and post-menopausal patients.
Patients and methods: A Cross-sectional observational study including 120 SLE female patients diagnosed according to 2012 ACR/SLICC criteria, above the age of 35.
Results: Twenty four (20%) patients had premature menopause, 35 (29.17%) patients had natural menopause, 61 (50.83%) patients were still menstruating. It was found that the age at menopause (either natural or premature menopause) ranged from 26 to 54 years with the mean 45.170 ± 7.278 years. There was a statistically significant negative correlation between LH and total SLEDAI (r= -0,178, P=0.052). It was also found a statistically significant positive correlation between FSH and cumulative Cyclophosphamide dose (r= 0.440, P< 0.001) and between LH and cumulative Cyclophosphamide dose (r=0.214, P=0.046).
Conclusion: The mean age at menopause (either natural or premature menopause) is 45 years. High LH (ovarian failure) is associated with lower disease activity. High cumulative Cyclophosphamide dose is associated with high FSH and LH (Ovarian failure).